Notably, these trials were performed at a time wheneffective medical prevention of CAD primarily consisted of statins, with no access tocontemporary agents such as PCSK9i monoclonals, inclisiran, icosapent ethyl, bempedoicacid, low-dose rivaroxaban, GLP1 receptor agonists, GLP1/GIP agonists, SGLT2inhibitors, SGLT1/2 inhibitors, and upcoming therapies targeting inflammation andlipoprotein(a). Here, GIP is linked to coronary artery disorder.